Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply

JAMA Ophthalmol. 2017 Mar 1;135(3):291-292. doi: 10.1001/jamaophthalmol.2016.5686.

¹ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland2Editor, JAMA Ophthalmology.
² Jaeb Center for Health Research, Tampa, Florida.
³ Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor5Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor6College of Engineering, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.

No abstract available

Publication types